Is IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.3% / 30% | 14.1% / 30% | 3.9% / 30% | 3.91% / 5% | ✓ HALAL |
| DJIM | 2.3% / 33% | 14.1% / 33% | 3.9% / 33% | 3.91% / 5% | ✓ HALAL |
| MSCI | 5.4% / 33% | 32.5% / 33% | 9.0% / 33% | 3.91% / 5% | ✓ HALAL |
| S&P | 2.3% / 33% | 14.1% / 33% | 3.9% / 33% | 3.91% / 5% | ✓ HALAL |
| FTSE | 5.4% / 33% | 32.5% / 33% | 9.0% / 50% | 3.91% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 34.3% | |
| Operating Margin | -84.7% | |
| Net Margin | -148.4% | |
| Return on Equity (ROE) | -55.5% | |
| Return on Assets (ROA) | -27.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$302M |
| Free Cash Flow | -$336M |
| Total Debt | $49M |
| Debt-to-Equity | 7.1 |
| Current Ratio | 3.2 |
| Total Assets | $913M |
Price & Trading
| Last Close | $3.69 |
| 50-Day MA | $3.32 |
| 200-Day MA | $2.57 |
| Avg Volume | 15.3M |
| Beta | 0.7 |
|
52-Week Range
$1.64
| |
About IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Purification Calculator
As a halal stock with 3.91% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is IOVANCE BIOTHERAPEUTICS, INC. (IOVA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), IOVANCE BIOTHERAPEUTICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is IOVANCE BIOTHERAPEUTICS, INC.'s debt ratio?
IOVANCE BIOTHERAPEUTICS, INC.'s debt ratio is 2.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.4%.
Does IOVANCE BIOTHERAPEUTICS, INC. require dividend purification?
Yes, IOVANCE BIOTHERAPEUTICS, INC. has an impermissible income ratio of 3.91%, which means 3.91% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are IOVANCE BIOTHERAPEUTICS, INC.'s key financial metrics?
IOVANCE BIOTHERAPEUTICS, INC. has a market capitalization of $1.4B, and revenue of $264M. The company maintains a gross margin of 34.3% and a net margin of -148.4%. Return on equity stands at -55.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.